Misplaced Pages

Mapracorat: Difference between revisions

Article snapshot taken from[REDACTED] with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editNext edit →Content deleted Content addedVisualWikitext
Revision as of 13:27, 6 January 2011 editAnypodetos (talk | contribs)Autopatrolled, Extended confirmed users, Pending changes reviewers, Rollbackers39,350 edits Phase III study started← Previous edit Revision as of 20:09, 2 March 2011 edit undo83.215.241.93 (talk) InChINext edit →
Line 13: Line 13:
| molecular_weight = 462.479 g/mol | molecular_weight = 462.479 g/mol
| smiles = c14OCCc4cc(F)cc1C(C)(C)CC(O)(C(F)(F)F)CNc(cccc2n3)c2ccc3C | smiles = c14OCCc4cc(F)cc1C(C)(C)CC(O)(C(F)(F)F)CNc(cccc2n3)c2ccc3C
| StdInChI = 1S/C25H26F4N2O2/c1-15-7-8-18-20(5-4-6-21(18)31-15)30-14-24(32,25(27,28)29)13-23(2,3)19-12-17(26)11-16-9-10-33-22(16)19/h4-8,11-12,30,32H,9-10,13-14H2,1-3H3/t24-/m1/s1
| StdInChIKey = VJGFOYBQOIPQFY-XMMPIXPASA-N
| bioavailability = | bioavailability =
| protein_bound = | protein_bound =

Revision as of 20:09, 2 March 2011

Pharmaceutical compound
Mapracorat
Clinical data
Routes of
administration		Topical (ointment, eye drops)
ATC code
  • none
Legal status
Legal status
  • Investigational
Identifiers
IUPAC name
  • (2R)-1,1,1-trifluoro-4-(5-fluoro-2,3-dihydro-1-benzofuran-7-yl)-4-methyl-2-methyl]pentan-2-ol
CAS Number
PubChem CID
CompTox Dashboard (EPA)
ECHA InfoCard100.217.969 Edit this at Wikidata
Chemical and physical data
FormulaC25H26F4N2O2
Molar mass462.479 g/mol g·mol
3D model (JSmol)
SMILES
  • c14OCCc4cc(F)cc1C(C)(C)CC(O)(C(F)(F)F)CNc(cccc2n3)c2ccc3C
InChI
  • InChI=1S/C25H26F4N2O2/c1-15-7-8-18-20(5-4-6-21(18)31-15)30-14-24(32,25(27,28)29)13-23(2,3)19-12-17(26)11-16-9-10-33-22(16)19/h4-8,11-12,30,32H,9-10,13-14H2,1-3H3/t24-/m1/s1
  • Key:VJGFOYBQOIPQFY-XMMPIXPASA-N

Mapracorat (INN, code names BOL-303242-X, ZK 245186) is an anti-inflammatory drug belonging to the experimental class of selective glucocorticoid receptor agonists (SEGRAs). It is in clinical trials for the topical treatment of atopic dermatitis and inflammation following cataract surgery. Preliminary investigation for the treatment of keratoconjunctivitis sicca has been conducted in cellular models.

Clinical trials

Phase II clinical trials with mapracorat started in summer 2009. One trial was a double blind dose finding study for an ointment against atopic dermatitis. It tested concentrations of 0.01%, 0.03% and 0.1% versus placebo over four weeks in around 64 patients. This trial was conducted by Intendis, a part of Bayer HealthCare Pharmaceuticals specialized on dermatology, and completed in September or October 2010. The other trial, also with a double blind design, evaluated an ophthalmic suspension for the treatment of inflammation following cataract surgery. Various concentrations and dosing schemes were tested versus placebo in about 550 patients. The study was conducted by Bausch & Lomb and completed in September 2010. Its successor study, a phase III trial, started in November 2010 and is scheduled to run until February 2012.

As of January 2011 no study results are available.

References

  1. ^ PMID 20824100
  2. ^ Clinical trial number NCT00944632 for "Dose Escalation of Different Concentrations of ZK 245186 in Atopic Dermatitis" at ClinicalTrials.gov
  3. ^ Clinical trial number NCT00905450 for "Evaluation of BOL-303242-X Versus Vehicle for the Treatment of Inflammation Following Cataract Surgery" at ClinicalTrials.gov
  4. Clinical trial number NCT01230125 for "Mapracorat Ophthalmic Suspension for the Treatment of Ocular Inflammation Following Cataract Surgery" at ClinicalTrials.gov


Stub icon

This dermatologic drug article is a stub. You can help Misplaced Pages by expanding it.

Categories:
Mapracorat: Difference between revisions Add topic